The efficacy of ramelteon, selective melatonin receptor agonist, during the critical care: MELIt Trial (Melatonin Evaluation of Lowered Inflammation in ICU Trial)

Trial Profile

The efficacy of ramelteon, selective melatonin receptor agonist, during the critical care: MELIt Trial (Melatonin Evaluation of Lowered Inflammation in ICU Trial)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Delirium; Inflammation
  • Focus Therapeutic Use
  • Acronyms MELIt Trial
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to completed.
    • 18 Aug 2015 According to the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.
    • 04 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top